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sribeiro@ibili.uc.ptMachado-Joseph’s disease is caused by a CAG trinucleotide repeat
expansion that is translated into an abnormally long polyglutamine tract
in the protein ataxin-3. Except for the polyglutamine region, proteins
associated with polyglutamine diseases are unrelated, and for all of these
diseases aggregates containing these proteins are the major components of
the nuclear proteinaceous deposits found in the brain. Aggregates of the
expanded proteins display amyloid-like morphological and biophysical
properties.
Human ataxin-3 containing a non-pathological number of glutamine
residues (14Q), as well as its Caenorhabditis elegans (1Q) orthologue, showed
a high tendency towards self-interaction and aggregation, under near-
physiological conditions. In order to understand the discrete steps in the
assembly process leading to ataxin-3 oligomerization, we have separated
chromatographically high molecular mass oligomers as well as medium
mass multimers of non-expanded ataxin-3. We show that: (a) oligomeriza-
tion occurs independently of the poly(Q)-repeat and it is accompanied by
an increase in b-structure; and (b) the first intermediate in the
oligomerization pathway is a Josephin domain-mediated dimer of ataxin-
3. Furthermore, non-expanded ataxin-3 oligomers are recognized by a
specific antibody that targets a conformational epitope present in soluble
cytotoxic species found in the fibrillization pathway of expanded
polyglutamine proteins and other amyloid-forming proteins. Imaging of
the oligomeric forms of the non-pathological protein using electron
microscopy reveals globular particles, as well as short chains of such
particles that likely mimic the initial stages in the fibrillogenesis pathway
occurring in the polyglutamine-expanded protein. Thus, they constitute
potential targets for therapeutic approaches in Machado-Joseph’s disease,
as well as valuable diagnostic markers in disease settings.
q 2005 Elsevier Ltd. All rights reserved.
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Several human disorders are caused by trinucleo-
tide expansions in a heterogeneous group of genes.1
CAG expansions leading to increased polygluta-
mine repeats within the affected proteins are
responsible for nine slowly progressive disorders
collectively known as polyglutamine (poly(Q))
diseases. Despite ubiquitous expression of both
the normal and disease proteins throughout thed.
Trapping Early Oligomers of Non-expanded Ataxin-3 643brain and other tissues, only a particular subset of
neurons is selectively affected in each disease.
Nuclear and sometimes cytoplasmatic neuronal
inclusions (NIs) containing the mutant proteins,
are now clearly established as the identifying
fingerprint of poly(Q) diseases.2,3 Longer poly(Q)
repeats cause more severe disease symptoms,
implying that the degree of toxicity is directly
proportional to the size of the repeat.
The structural and functional effects of poly(Q)
expansions in the affected proteins as well as the
mechanisms of polyglutamine toxicity are still not
clear. An enormous research effort has been put into
understanding the structure of polyglutamine and
the structural changes induced by polyglutamine
expansion.4,5 Current experimental data show that,
independently of the repeat length, monomeric
polyglutamine sequences exist predominantly in a
random coil conformation. A conformational tran-
sition occurs upon aggregation: in close connection
with the pathological threshold in polyglutamino-
pathies, the tendency to aggregate into b-rich
fibrillar structures increases with poly(Q) length.6
The amyloid nature of these polyglutamine
insoluble structures has been demonstrated by
numerous experiments in vitro7–9 and in vivo.7,10
Furthermore, poly(Q) aggregates are recognized by
“pan-amyloid” antibodies able to associate with
generic amyloid epitopes in fibrils formed from a
diverse number of proteins.11 Whether the cellularFigure 1. Sequence alignment of human and C. elegans ata
MJD1-1 (SwissPROT: P54252 variant VSP_002784), MJD2-1
variant VAR_013689), are compared with the C. elegans ataxin
residues are shaded in light green. The catalytic Josephin dom
filled blue circles below the alignment. Notice that only ataxin
blue) after the poly(Q) tract (red left-arrow triangles below th
sequence. Residues important for catalysis are highlighted by
alignment was preformed with TCOFFEE60 and the Figure wtoxicity is triggered by the pathogenic disease
protein alone, by the putative intermediates of the
fibrillization pathway, or by the soluble mature
fibrils, is still a matter of debate.12 In this line,
protofibrillar intermediates in polyglutamine pro-
teins have already been identified.9,13,14 Because
poly(Q) aggregates exhibit most of the characteristic
features of amyloid structures,15 the formation of
the mature fibrils probably occurs via early
assembly intermediates that have been implicated
as the toxic species responsible for cell dysfunction
and neuronal loss.16,17
Expanded ataxin-3 is found in nuclear
inclusions18 in Machado-Joseph’s disease (MJD), a
disease that has the highest prevalence in the
Azores islands of Flores and Sao Miguel. Although
the precise cellular role(s) of ataxin-3 are still not
fully characterized, its function as a polyubiquitin
hydrolase and its role as a suppressor of poly(Q)-
induced neurodegeneration is just starting to be
unveiled.19–22 Ataxin-3 is a modular protein com-
prised of a conserved N-terminal Josephin
domain,23,24 containing the catalytic cysteine resi-
due, followed by two ubiquitin interacting motif
(UIM) domains and the poly(Q) repeat domain.
Four different transcript variants of the human
protein (Figure 1) have been identified, although
their functional relevance and expression in vivo are
still unknown.25 As observed in other polygluta-
minopathies, there is a threshold polyglutaminexin-3. Three of the four known human ataxin-3 isoforms:
(SwissPROT: P54252) and MJD1a (SwissPROT: P54252
-3-like protein (MJDL-CE, SwissPROT: O17850). Identical
ain is boxed in red and the UIM domains are indicated by
-3 variant MJD1-1 contains a third UIM domain (boxed in
e alignment). Numbering refers to the MJD1-1 amino acid
orange triangles below the alignment. Multiple sequence
as prepared with ALSCRIPT.61
Figure 2. Non-expanded ataxin-3 oligomerizes under
near-physiological conditions. (a) Monomeric human
ataxin-3 can be separated from high molecular mass
oligomers by size-exclusion chromatography (Hiprep 26/
60 Sephacryl S-200 HR). Elution profiles of native human
ataxin-3 eluted from the HisTrap column with 100 mM
(black line) imidazole, monitored at 280 nm. The elution
profile, in combination with the SDS-PAGE analysis of the
isolated fractions (inset A), indicate that the purified
protein exists in different oligomeric forms. The protein
elutes with a predominant monomeric peak (peak 3),
although partially contaminated with the other oligo-
meric forms (peaks 1 and 2). The oligomeric species
partition into two overlapping peaks, one eluting around
106 ml (peak 2), possibly representing a mixture of homo-
multimers with different subunit compositions, and the
void volume eluate (peak 1), representing higher-order
soluble ataxin-3 oligomers. Monomeric ataxin-3 elutes
faster than expected for a globular 44 kDa protein, but this
behaviour might reflect the non-spherical shape of this
protein.8 For comparison purposes, the elution profile of
the catalytic Josephin domain (peak 4, predicted molecu-
lar mass 23 kDa) is also shown (broken black line); the
black arrow highlights the shoulder preceding the major
peak of the Josephin domain, representing Josephin
dimers (see the text and Figure 3). The purified
monomeric form of full-length ataxin-3 and the Josephin
domain alone were concentrated to w10 mg/ml and
analysed by SDS-PAGE under reducing conditions (inset
B). (b) Size-exclusion chromatography (Hiprep 26/60
Sephacryl S-200 HR) elution profile of MJDL-CE, mon-
itored at 280 nm. The protein applied to the column was
eluted from the HisTrap column with 500 mM imidazole,
and it is separated into three well-resolved peaks, of high
molecular mass oligomers (peak 1), multimers (peak 2),
and monomers (peak 3). Fractions of 5 ml were collected
and analysed by SDS-PAGE (12% polyacrylamide gels)
(inset A). All gels are stained with Coomassie brilliant
blue. Asterisks (*) denote the positions of the molecular
644 Trapping Early Oligomers of Non-expanded Ataxin-3length (14–40 residues) for ataxin-3, below which
the pathways leading to selective neural loss are not
triggered within the human lifespan.26 Remarkably,
it has been shown that non-expanded protein can
also form amyloid fibrils with increased b-sheet
structure upon partial unfolding induced by
increased temperature and pressure,27,28 as well as
by chemical denaturation.29
In order to understand the structural mechanisms
that link polyglutamine expansion with disease,
and to clarify the role of the poly(Q) repeats in
ataxin-3 aggregation, we expressed and purified the
homologous ataxin-3 protein from Homo sapiens
(14Q), and the orthologue protein fromCaenorhabditis
elegans (26.9% identity, 1Q). Human ataxin-3, as
well as heterologous C. elegans protein form, under
near-native conditions, high molecular mass
(HMM) oligomers and smaller multimers that we
isolated chromatographically from the monomeric
forms for further characterization.ResultsNon-expanded ataxin-3 self-associates to form
soluble high molecular mass oligomers
We have cloned and over-produced in Eschrerichia
coli the isoform MJD1-1 (Figure 1) of non-expanded
human ataxin-3, with a poly(Q) tract of 14 residues,
and the C. elegans ataxin-3-like protein (MJDL-CE,
Figure 1), containing a single glutamine residue in
the region corresponding to the poly(Q). The
C. elegans ataxin-3-like protein and the human
protein display around 27% identity, being mostly
similar within the catalytic Josephin domain (43%
identity).
Gel-filtration chromatography analysis of the
ataxin-3 containing fractions, eluted from the
metaloaffinity column, showed that for both
human (14Q) and C. elegans (1Q) proteins soluble
oligomeric and monomeric forms coexist. These
results indicate that ataxin-3 is able to self-assemble
into homo-multimeric species of different sizes,
independently of the length of the poly(Q)-tract
(Figure 2). The gel-filtration profile of protein
fractions purified from the HisTrap column showed
that human ataxin-3 separates into a well-resolved
predominant peak containing monomeric protein
(Figure 2(a), peak 3), and two overlapping oligo-
meric fractions (Figure 2(a), peaks 1 and 2). In
contrast, MJDL-CE separates into three major well-
resolved peaks (see Figure 2(b)) that we called
HMM oligomers (peak 1), multimers (peak 2), and
monomers (peak 3). Despite the fact that MJDL-CE
contains a single glutamine rersidue, this proteinmass standards, from left to right: blue dextran
(2000 kDa), thyroglobulin (669 kDa), catalase (232 kDa),
aldolase (158 kDa), bovine serum albumin (67 kDa),
ovalbumin (43 kDa), and chymotrypsinogen (25 kDa).
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and it is less stable than the human protein,
showing a much greater tendency towards precipi-
tation and degradation.
Although the predicted molecular mass of
human ataxin-3 is w44 kDa (Figure 2(a), inset A),
the lower molecular mass peak (peak 3) elutes from
the gel-filtration column before the 67 kDa molecu-
lar mass marker. This behaviour is observed also for
monomeric MJDL-CE (Figure 2(b), peak 3; expected
molecular mass w39 kDa). The anomalous
migration observed for the two proteins likely
indicates that both MJD1-1 and MJDL-CE display
an overall elongated shape, similar to what has been
observed for isoform MJD1a (Figure 1).8
To further evaluate the oligomerization state of
the soluble ataxin-3 aggregates, aliquots from the
peaks separated by gel-filtration chromatography
were crosslinked with glutaraldehyde to fix the
aggregation state of the proteins, allowing their
analysis under denaturing conditions by SDS-PAGE
(Figure 3). This confirmed that the lower molecular
mass peaks (Figure 2(a) and (b), peak 3) do
correspond to monomeric species. The faint band
of dimers observed upon longer incubations of
monomeric ataxin-3 with glutaraldehyde
(Figure 3(a)), likely represents non-specific cross-
linking effects resulting from random collisions of
monomers. Similar results are observed upon
crosslinking of lysozyme under identical exper-
imental conditions (data not shown). The MJD1-1
protein eluting just before the monomer, with a
calculated molecular mass of 140 kDa (Figure 2(a),
peak 2), is likely enriched in ataxin-3 dimers asFigure 3. Ataxin-3 self-assembles into multimeric
species composed of dimers, pentamers and hexamers.
Crosslinking was performed with 0.02% glutaraldehyde
for human ataxin-3 fractions collected from (a) peak 3 and
(b) peak 2 and for the C. elegans ataxin-3 fractions
collected from (c) peaks 2 and 3. The protein was
incubated at room temperature and 10 ml aliquots were
collected at the indicated time-points, the reaction was
stopped by adding sample buffer and heating to 100 8C
for 5 min. (d) Crosslinking of protein isolated from the
small shoulder preceding the major peak of the Josephin
domain, indicating that this domain alone is able to
oligomerize. Samples were analyzed by SDS-PAGE and
the gels in (a), (b) and (d) were stained with Coomassie
brilliant blue. The gel in (c) was stained with silver.observed by the appearance of a predominant
w100 kDa species on SDS-PAGE, accompanied by
the simultaneous disappearance of the 44 kDa
band, after crosslinking with glutaraldehyde
(Figure 3(a)). Those dimers are not homogeneous
and consistently appear contaminated with two
discrete bands with molecular mass greater than
250 kDa, possibly representing MJD1-1 pentamers
and hexamers, and for this reason we refer to these
species as multimers. Those multimers of the
human protein could not be fully separated from
the other oligomeric species and are very unstable,
quickly converting into higher molecular mass
structures (see Supplementary Data, Figure 1).
Crosslinking analysis of the MJDL-CE intermediate
peak (Figure 2(b), peak 2) indicates that it is also a
dimer separating very well from higher molecular
mass oligomers (Figure 3(c)). In contrast, cross-
linking of the HMM oligomers (Figure 2(a) and (b);
peak 1) yielded species that did not enter the gel,
even when lower concentrations of glutaraldehyde
were used (data not shown). Those species have
apparent molecular mass of 300–600 kDa, as calcu-
lated by comparison with known molecular mass
standards in gel-filtration chromatography.
Oligomer formation seems to be an intrinsic
property of ataxin-3 proteins, independent of the
length of the polyglutamine domain. In agreement,
in vitro cell studies with cellular models expressing
expanded and non-expanded ataxin-3 have shown
that both proteins form large macromolecular
complexes.30 Indeed, under the same experimental
conditions we can observe the formation of HMM
oligomers of mouse (6Q) and chicken (7Q) ataxin-3
homologues (S. M.-R., unpublished results). Con-
sidering that the domain with the highest degree of
conservation across species is the Josephin domain,
we have decided to further investigate the proper-
ties of this catalytic domain of human ataxin-3. The
Josephin domain migrates with the predicted
molecular mass on the gel-filtration column
(Figure 2(a), inset B), as expected from a globular
protein, and in agreement with previously reported
experimental data.23,31 However, no HMM oligo-
meric species are observed during the purification
of the Josephin domain alone, although the
presence of a small shoulder preceding the major
peak (Figure 2(a), peak 4), indicates the presence of
a small percentage of dimers that cannot be
separated completely from the monomeric forms.
The partial dimerization of the Josephin domain
was confirmed by crosslinking with glutaraldehyde
(Figure 3(d)). Under partially denaturing con-
ditions, we did observe precipitation of the protein
into amyloid-like structures capable of binding
Congo red (S. M.-R., unpublished results) as
reported recently.31
Altogether, our results provide evidence that
non-expanded ataxin-3 has an intrinsic propensity
to oligomerize, and that oligomerization is not
mediated by direct poly(Q) interactions. Further-
more, the fact that we could observe the formation
of dimers of both full-length human and C. elegans
646 Trapping Early Oligomers of Non-expanded Ataxin-3ataxin-3, and that the truncated human Josephin
domain alone shows propensity for dimerization,
clearly implicates this highly conserved domain in
ataxin-3 dimerization. Further oligomerization
events seem to be mediated and/or induced, at
least under our experimental conditions, by the
other protein domains.Circular dichroism analysis suggests that a
conformational change occurs upon
oligomerization
To further characterize the nature and properties
of the oligomeric forms of ataxin-3, a combination of
methods has been used. They include binding to
histological dyes, such as thioflavin T (ThT), and
circular dichroism (CD) to elucidate the constituent
secondary structure.Figure 4. Ataxin-3 early oligomers are b-rich amyloid-
like structures. (a) The CD spectra of (a1) human and (a2)
C. elegans ataxin-3 in the monomeric and oligomeric
forms. The secondary structure content was calculated
using the Contin method and is displayed (in %). The
b-sheet conversion accompanies protein aggregation and
is more marked for human ataxin-3. (b) Thioflavin-T
binding assays of (b1) human and (b2) C. elegans ataxin-3.
The oligomeric species are all thioflavin-T positive,
reflecting the amyloid-like properties of those early
ataxin-3 aggregates. Multimers (*) of human ataxin-3 are
a heterogeneous mixture of different oligomerization
states (see Supplementary Data, Figure 1).The secondary structure of MJD1-1 in the mono-
meric and in the oligomeric forms was determined by
CD spectroscopy. The spectra of the monomeric form
of the human protein display a high content of
a-helix, 36%, in agreement with previous results,8,23
and a relatively lower percentage of b-sheet (16%),
and b-turn (17%, Figure 4(a)). There is also a
significant fraction of random coil conformation
(31%), suggesting the presence of a flexible portion
of the protein, which is in agreement with previous
studies.23 The relative proportion of a-helix, b-sheet
and b-turn is relatively well conserved for MJDL-CE,
indicating a conservation of the overall secondary
structure for this ataxin-3 ortholog (Figure 4(a)).
Oligomerization induces important alterations in
the secondary structure of the protein. CD analysis
of the HMM MJD1-1 oligomers, that display greater
homogeneity than the multimeric species after a
freeze–thaw cycle (see Supplementary Data,
Figure 1), show that there is a drastic reduction in
the a-helix content accompanied by the proportional
increase in b-sheet structure. The b-turn and random
coil contents show minor alterations upon oligo-
merization (Figure 4(a)). The C. elegans ataxin-3-like
protein (1Q) displays the same behaviour as the
human ataxin-3 (14Q) (increase in b-sheet and
decrease in a-helix content), although to a signifi-
cantly lesser extent. The HMM oligomers, and even
the earlier multimeric species of both the human and
C. elegans proteins, are ThT-positive (Figure 4(b)).
This fluorescent dye is known to bind b-rich fibrillar
structures.
From our observations, freezing (at K80 8C) and
thawing the protein between purification steps can
increase the proportion of HMM oligomers up to
90% of the total soluble MJD1-1 ataxin-3 purified.
Furthermore, it consistently forms fibrillar precipi-
tates upon thawing. This susceptibility towards
aggregation induced by freezing has been reported
for poly(Q)-containing peptides.6 Those ataxin-3
precipitates bind Congo red, a known reporter of
repetitive b-structures, and display red-green
birefringence characteristic of amyloid-like fibrils
(Figure 5(a)). Electron microscopy analysis revealed
the presence of elongated fibrils and a small
number of granular aggregates (Figure 5(b)).
These structures are reminiscent of the precursor
aggregates (protofibrils) that precede formation of
amyloid fibrils.16,32,33
Seeding effects in ataxin-3 aggregation
The aggregation progress of poly(Q) proteins can
be followed consistently using techniques such as
CD spectroscopy, HPLC, light-scattering and ThT
fluorescence.34 In this work, we monitored the
polymerisation kinetics of MJD1-1 by ThT fluores-
cence. Furthermore, we evaluated the seeding effect
in the aggregation progress by adding, at time
zero, a small amount (4%, w/w) of dimers and of
HMM oligomers (10%, w/w). We observed that
there is an initial lag phase, which is reduced
significantly by seeding with pre-formed dimers or
Figure 5. Amyloid-like properties of ataxin-3 insoluble
aggregates. Non-expanded human ataxin-3 precipitates
into amyloid-like structures (a) as detected by red-green
birefringence upon binding Congo red and (b) electron
micrographs of the negatively stained insoluble material.
Figure 6. Dimers and HMM oligomers seed human
ataxin-3 fibril formation. Aggregation kinetics at 37 8C of
human ataxin-3, as monitored by thioflavin-T fluor-
escence. Polymerisation progress at pH 7.5 without seed
(†), with addition at time 0 of 4% (w/w) of preformed
dimers (-), and with addition at time 0 of 10% (w/w) of
high molecular mass soluble oligomers (%). Aggregation
follows a nuclear-growth model with a marked seeding
effect.
Trapping Early Oligomers of Non-expanded Ataxin-3 647HMM oligomers, followed by a rapid growth phase
(Figure 6). This behaviour is typical of poly(Q)
aggregation in vitro,35 and it suggests a nuclear-
growth polymerisation model.
Without the addition of preformed oligomers, we
observed a complete time-course of aggregation of
around 90 h at 37 8C and an initial lag phase of less
than 10 h. A previous work on the MJD1a variants
of ataxin-3 (Figure 1) containing 15, 28 and 50
residues in their glutamine tract, reported no
aggregation, as monitored by ThT fluorescence,
within 24 h for ataxin-3(15Q) and ataxin-3(28Q),
and aggregation to near-completion of the patho-
logical ataxin-3(50Q) in 24 h.36 Indeed, we have
observed for the MJD1-1 variant that during the first
24 h of incubation at 37 8C the increase of ThT
fluorescence is relatively small. This initial stage is
followed by a rapid growth phase in the case of the
MJD1-1 variant, which can be clearly monitored by
ThT fluorescence.
The complete time-course of polymerisation ofThe fibril diameter is 8–12 nm. The short and curly fibrils
are characteristic of protofibrils or “immature” amyloid
fibrils. Arrows show granular oligomeric structures. The
scale bar represents 100 nm.
648 Trapping Early Oligomers of Non-expanded Ataxin-3MJD1-1, and the length of the initial lag phase in
particular, are very sensitive to seeding with
dimers, multimers (data not shown) and HMM
oligomers. The strong effect of adding a small
amount of dimers at time zero suggests that
nucleation involves either the refolding of the
monomer, as was proposed by Chen and co-
workers based on the aggregation kinetics of
poly(Q) peptides,34 or the formation of a dimer.
Transmission electron microscopy reveals
the morphological characteristics of
non-pathological ataxin-3 along the aggregation
pathway
We are currently able to sample three distinct
soluble oligomeric states of ataxin-3: non-globular
monomers, multimers, and HMM oligomers. Those
profiles are obtained consistently by gel-filtrationchromatography, independently of the total con-
centration of ataxin-3. The HMM oligomers are
rather homogeneous and remain stable upon
storage at K80 8C. The multimers of human
ataxin-3 are not particularly stable, converting
quickly to higher molecular mass forms. The
heterogeneity of the multimeric species is higher
for the human than for the C. elegans protein.
The multimers of MJD1-1 were separated freshly
by gel-filtration chromatography (Supplementary
Data, Figure 1) and electron microscopy was used to
examine the structure of isolated species in the
individual peaks. Examination of the dimeric and of
the oligomeric samples by transmission electron
microscopy reveals the presence of spherical
structures, although the corresponding diameter
for the oligomers (w7 nm) (Figure 7) seems slightly
larger than the diameter of the dimers (w6 nm)
(Supplementary Data, Figure 1). Moreover, theFigure 7. Spherical ataxin-3
oligomers are recognized by the
anti-oligomer antibody. Character-
isation of the different species of
human recombinant ataxin-3 by
dot blot analysis and electron
microscopy. Soluble HMM oligo-
mers, multimers and monomers of
(a) human and (c) C. elegans
recombinant ataxin-3 were
applied to a nitrocellulose mem-
brane and either probed with
oligomer-specific antibody or
anti-His antibody. Oligomer-
specific antibody recognized all
oligomeric species, and did not
recognize monomers of recombi-
nant ataxin-3, whereas anti-His
antibody recognized all oligomer-
ization forms of the recombinant
protein (data not shown). EM
images show the spherical mor-
phology of (b) human and (d)
C. elegans ataxin-3 oligomers (the
scale bars represent 100 nm).
(e) The anti-oligomer antibody
recognizes an epitope present in
the dimeric Josephin domain that
is absent from the monomeric
form of this protein.
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residual population consisting of two or three aligned
rod-like structures is present, which should corre-
spond to the early stage of the elongation phase. The
higher-order soluble aggregates have an elongated
curvilinear structure. They are unbranched, with
diameters of 7–9 nm and length up to 200 nm
(Figure 7). These structures precede the formation of
the protofilaments, which are mostly unbranched
with a variable length up to 2 mm and a diameter of
8–12 nm (Figure 5). Also present along with these
precursors of the mature fibrils are rod-like aggre-
gates with diameters of 20–30 nm. The beaded
morphology and width dimensions of the fibrils
resemble those formed by expanded (78Q) ataxin-3.8
The MJDL-CE protein is separated by size-
exclusion chromatography into three major well-
resolved peaks (see Figure 2(b)), HMM oligomers,
multimers and monomers. These three distinct
samples were examined by electron microscopy.
The monomeric sample was constituted by spherical
structures and was, as expected, homogeneous
(data not shown). The sample containing multimers
was more heterogeneous and there were already
aggregates, forming a few spherical structures
(Figure 7). The HMM oligomers are formed by
slightly elongated structures, with dimensions in
the shorter direction of w7 nm and in the longer
direction ranging between 7 nm and 25 nm.
Characterisation of the oligomer-specific
immunoreactivity
It has been shown recently that amyloid-b peptide,
a-synuclein and poly(Q) peptides adopt a structural
epitope found only in soluble oligomeric structures,
which correlates with their cellular toxicity.16,17,37
Ataxin-3 multimers and HMM oligomers, bind
the anti-oligomer antibody (Figure 7) independently
of the length of the poly(Q) tract, joining the
growing family of amyloidogenic intermediates
that share a toxic conformation. This suggests that
they might represent toxic intermediates with
relevance for the pathogenesis of Machado-Joseph’s
disease, as shown for other amyloid-related degen-
erative diseases. Interestingly, the protein fraction
enriched in a dimeric form of the Josephin domain
(Figure 3(d)), also exposes an epitope clearly
recognized by the anti-oligomer antibody that is
absent from the monomeric form of the protein
(Figure 7(e)). This indicates that dimerization of the
Josephin domain is accompanied by a structural
rearrangement that might constitute the first
misfolding event of the ataxin-3 aggregation pathway.Discussion
Poly(Q)-independent oligomerization
Amyloid is generally considered to be a non-
native quaternary structure generated by defects in
protein folding or clearance pathways. A diversenumber of proteins with an abnormally long
polyglutamine expansion display a strong tendency
to form amyloid-like aggregates and are implicated
in several progressive disorders. Ataxin-3, the
smallest of these poly(Q) proteins, is associated
with Machado-Joseph’s disease.
Using human ataxin-3 containing a non-patho-
logical number of glutamine residues (14Q), the
C. elegans (1Q) orthologue we were able to (a) prove
that the glutamine expansion is not essential for
ataxin-3 amyloid fibril formation in vitro, and (b)
trap for the first time early oligomers that are
recognized by an oligomer-specific antibody,
known to target soluble cytotoxic intermediates of
many amyloidogenic proteins, including poly(Q)
proteins.16 Previous studies showed the formation
of insoluble amyloid fibrils by non-expanded
ataxin-3,27–29 and specifically by the isolated Jose-
phin domain.31 Those studies, focused on the end-
stage of ataxin-3 aggregation reactions, showed
non-expanded protein aggregation following par-
tial unfolding induced by pressure, temperature or
chemical denaturation. The formation of amyloid
fibrils upon partial protein denaturation has been
demonstrated for a number of proteins, even those
unrelated to amyloid pathologies.38 In contrast, we
have established near-physiological experimental
conditions whereby non-pathological ataxin-3
forms soluble oligomeric structures. In agreement
with previous results showing that the Josephin
domain alone is able to form insoluble amyloid
fibrils,31 our results demonstrate that at least one of
the protein oligomerization sites also maps to this
catalytic domain. Even though this domain seems
to be necessary for ataxin-3 oligomerization, our
current CD data show also that the extent of
the a-helix to b-sheet structure conversion upon
oligomerization correlates with the length of the
poly(Q) tract.
The heterogeneity of ataxin-3 oligomerization
resembles very closely the data obtained for
oligomerization of the chymotrypsin inhibitor 2
upon introduction of a four to ten residue poly(Q)
stretch in the inhibitory loop.39 As shown in the
crystal structure of the isolated dimer, oligomeriza-
tion occurred by a domain swapping mechanism,40
and, although induced by the introduction of a
polyglutamine repeat, was not mediated by the
direct poly(Q) association.41 All our present data
indicate that a similar mechanism could induce the
first steps in ataxin-3 oligomerization and that
this association, most probably mediated by the
Josephin domain, does not involve direct inter-
glutamine interactions. The 3D domain swapping is
a mechanism for proteins to form oligomers by
exchanging identical domains,42 and has been
proposed as a possible mechanism leading to
amyloid formation.43 The presence of self-associ-
ation regions with relevance for protein aggregation
outside the poly(Q) tract has been described for
ataxin-1.44,45 Furthermore, it was demonstrated
that high levels of wild-type ataxin-1 can cause
degenerative phenotypes similar to those caused by
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might have more than one stable conformation,
and a certain percentage of the non-expanded
protein does misfold into a pathogenic confor-
mation.46 This trend for the presence of self-
association domains in proteins distant from the
homopolymeric amino acid expansion has been
observed for PABPN1, a protein associated with
oculopharyngeal muscular dystrophy upon
expansion of a polyalanine region.47 It is becoming
clear that although poly(Q) (as well as polyalanine)
repeats are themselves toxic, the sequence and
structure of the proteins carrying the poly(Q) tracts
have important roles in defining the course and
specificity of the disease.48 Those sequences deter-
mine subcellular localization, specify interactions
with other macromolecules within the cell and can
certainly modulate the natural conformational
heterogeneity of the protein.
Is a dimer formed by Josephin domain assembly
the first intermediate in ataxin-3
oligomerization?
At physiological temperature, the aggregation of
the monomeric form of human ataxin-3 (14Q) into
amyloid-like structures takes around 90 h as
monitored by the ThT binding assay. Moreover, it
follows a sigmoidal-type time-response, suggesting
that the nucleation is the controlling step of the
aggregation pathway.49 We have also observed a
seeding effect when dimers, multimers or HMM
oligomers are added to the monomeric form of the
protein. Our results can be interpreted in light of a
nuclear-growth polymerisation model,49,50 consist-
ing of a time-controlled nucleation phase during
which only a small part of the soluble protein
participates, followed by an elongation phase
during which the soluble monomers are recruited
into the growing fibre. Although our current
experimental data do not allow us to completely
trace the pathway of human ataxin-3 fibrillization,
it is tempting to assume that the first oligomeric
species in this pathway is a short-lived dimer,
which quickly converts to larger, heterogeneous
oligomeric species. The C. elegans ataxin-3 (1Q)
dimer, although degrading very fast, could be well
isolated from the HMM oligomers. We observed
that freshly isolated dimers of MJDL-CE are
ThT-positive (Figure 4(b)), display an increased
b-sheet content (Figure 4(a)), and bind the anti-
oligomer antibody. These results seem to hint that
the first b-rich intermediate within the pathway of
large-scale oligomerization is a dimer, formed by
the full-length protein; specifically, by the Josephin
domain. Dimerization implies a conformational
change that exposes a specific epitope recognized
by the anti-oligomer antibody. Further aggrega-
tion/extension events could involve other
protein domains. We are presently pursuing
experimental conditions that will allow us to
optimize the separation and stabilization of the
dimeric intermediates in order to further study theirstructural properties. Ataxin-3 dimers will clearly
be preferential targets for therapy in MJD.
Biological relevance of ataxin-3 oligomerization:
implications for Machado-Joseph’s disease
We have demonstrated that non-expanded
ataxin-3 has a natural tendency to oligomerize
into b-rich ordered structures. Small spherical
particles and larger curvilinear structures resulting
from their linear association could be observed by
electron microscopy. As observed for other amyloid
forming proteins, we expect that ataxin-3 neuro-
toxicity arises from those soluble oligomeric
species.16,17,37 A number of reports stress the
importance of oligomeric intermediates as the
major cytotoxic species in various forms of amyl-
oidogenesis,51–54 even arguing that formation of
insoluble inclusions might constitute a protective
mechanism.55
Non-pathological recombinant ataxin-3 forms
oligomers in vitro, displaying a pathogenic confor-
mation, under physiological conditions. In vivo,
both non-expanded and expanded forms of ataxin-3
have been detected within nuclear inclusions,56–58
reinforcing the role of protein domains outside the
expanded poly(Q)-tract in protein aggregation and
disease pathogenesis. In the case of ataxin-3, one of
the regions with propensity for oligomerization has
been mapped to the Josephin domain. Thus, a
tight control of the protein microenvironment by
post-translational modifications, intracellular local-
ization and/or interaction with specific macro-
molecular partners is thus crucial for controlling
the formation of toxic intermediates by the non-
expanded protein in vivo. Expansion of the poly-
glutamine, within the normal cell environment,
probably triggers extremely small conformational
changes36 that persistently interfere with macro-
molecular interactions, thus continuously inducing
the exposure of protein regions with high propen-
sity to misfold and oligomerize. In agreement,
polyglutamine expansion diseases are generally
late-onset, reflecting long in vivo lag phases. Upon
aging, the ability of the cell to deal with abnormal
proteins decreases and favours the accumulation of
toxic intermediates that induce cell damage.
It is our working hypothesis that while for the
disease protein oligomerization can occur under
physiological conditions, similar changes can occur
in non-disease proteins under partially unfavour-
able conditions or when the cellular interaction
partners are absent. Reduction of the poly(Q) length
brings oligomerization rates into an experimentally
accessible time-window, allowing us to capture the
early stages of the elongation phase of the mature
ataxin-3 amyloid fibrils. The search for the patho-
genic protein aggregates has practical implications
because their formation and the proteins with
which they interact are potential targets for
therapeutic intervention. Thus, studying the
aggregation pathway of non-expanded ataxin-3
will provide important clues about the early
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can monitor the formation of the amyloid pre-
cursors, which includes the isolation of early
oligomers, we are now able to screen drugs that
may interfere with the aggregation process and
even identify at which stage of the polymerization
they act.Materials and Methods
Plasmid construction
A construct encoding the human ataxin-3 cDNA
corresponding to the splice variant MJD1-1 (Swiss-Prot
P54252_2, variant VSP_002784) has been described.25 The
EST clone yk77c4 (kindly provided by Yuji Kowara)
corresponding to C. elegans mjd-1 cDNA was sequenced
and its missing 5 0 end completed using the RACE system
(Gibco) following the manufacturer’s instructions. The
cDNA was obtained from total RNA using random
primers. The PCR reaction was performed using the
reverse primer ceNde 5 0-GCA CAA ACC AGT GCT CTC
TGA G-3 0 and SL1 primer (spliced leader) with an
additional PstI restriction site 5 0-GAG GCT GCA GGT
TTA ATT ACC CAA GTT TGA G-3 0. The fragment was
subcloned into the NdeI and PstI restriction sites of the
initial yk77c4 construct and the full-length cDNA plasmid
obtained (ceMJD) was confirmed by sequencing.
The full-length cDNAs encoding MJD gene splice
variant MJD1-1, and the C. elegans orthologue protein
were first amplified by PCR using primers including the
5 0 and 3 0 attB site-specific recombination sequences
(Gateway Cloning System, Invitrogen Life Technologies)
attB1-MJD (5 0-GGG GAC AAG TTT GTA CAA AAA AGC
AGG CTG GAT GGA GTC CAT CTT CCA CGA G-3 0)/
attB2-MJD1-1 (5 0-GGG GAC CAC TTT GTA CAA GAA
AGC TGG GTC TTA TTT TTT TCC TTC TGT TTT 3 0),
attB1-ceMJD (5 0-GGG GAC AAG TTT GTA CAA AAA
AGC AGG CTG GAT GTC AAA AGA CGA TCC GAT
C-3 0)/attB2-ceMJD (5 0-GGG GAC CAC TTT GTA CAA
GAA AGC TGG GTC TTA TTT TTC ATC GTT CCT CTC-
3 0). These attB-PCR products were cloned into pDONR201
vectors (Invitrogen Life Technologies), and the latter
subcloned into pDEST17 expression vectors through site-
specific recombination, using the Gateway Cloning
System, according to the manufacturer’s protocol.
Plasmid pDEST17-J1, encoding the catalytic Josephin
domain of human ataxin-3, was obtained by introduction
of a stop codon mutation at position 548–550 in the open
reading frame, through QuickChange Site-Directed
Mutagenesis (Stratagene). The mutagenesis primers
were: Jos-1_For: 5 0CGA AGC TGA CCA ACT CCT ACA
GAT GAT TAG GTG ACA ACA GAT GCC TCG ACC3 0
and Jos-1_Rev: 5 0GGT CGA GGC ATC TGT TGT CAC
CTA ATC ATC TGT AGG AGT TGG TCA GCT TCG3 0. All
bacterial expression constructs were verified by restric-
tion enzyme digestion and automatic sequencing.
Protein expression and purification
The hexahistidine-tagged proteins were expressed in
E. coli BL21(DE3)-SI cells (Invitrogen Life Technologies).
Cells were grown at 37 8C in Luria broth medium without
NaCl containing 100 mg/l of ampicillin and 0.2% (w/v)
glucose. When cultures reached an absorbance at 600 nm
of 0.5–0.7, expression of the fusion protein was inducedby adding NaCl to a final concentration of 300 mM. After
3–4 h induction at 30 8C, the cells were collected by
centrifugation, resuspended in cell lysis buffer L (25 mM
sodium phosphate (pH 7.5), 500 mM NaCl, 10 mM
imidazole) containing 50 mg/l of lysozyme and frozen
at K20 8C. Before purification, a protease inhibitor
cocktail (Complete EDTA-free, Roche) was added to the
protein extract, and the supernatant obtained after
centrifugation was applied to a HisTrap chelating column
(Amersham Biosciences) and eluted in three steps by
addition of buffer L containing 50 mM, 100 mM and
500 mM imidazole. Fractions suitable for further purifi-
cation were selected by SDS-PAGE analysis. The fractions
eluting after metalloaffinity chromatography (w10 ml)
were applied to a Hiprep 26/60 column equilibrated in
buffer A (20 mM Hepes (pH 7.5), 200 mM NaCl, 5% (v/v)
glycerol) and eluted with a flow rate of 0.5 ml/min at
6 8C. The eluted proteins were monitored at 280 nm and
compared to the elution profile of the following molecular
mass standards: blue dextran (2000 kDa), 87.4 ml; thyr-
oglobulin (669 kDa), 87.81 ml; ferritin (440 kDa), 90.02 ml;
catalase (232 kDa), 104.3 ml; aldolase (158 kDa), 106.5 ml;
bovine serum albumin (67 kDa), 125.3 ml; ovalbumin
(43 kDa), 138.9 ml; and chymotrypsinogen A (25 kDa),
173.8 ml. After analysis by SDS-PAGE, and analytical gel-
filtration chromatography (Superose 12 10/300 GL) the
purest fractions were pooled and concentrated on
Vivaspin15 concentrators (cutoff 10 kDa, Vivascience,
Sartorius) to 2–10 mg/ml, immediately frozen in liquid
nitrogen and stored at K80 8C. Protein concentrations
were determined by measuring the absorbance at 280 nm
using extinction coefficients of 36,160 MK1 cmK1, 34,
640 MK1 cmK1 and 34,760 MK1 cmK1 for human ataxin-3,
C. elegans ataxin-3 and the Josephin domain, respectively.
In order to confirm purity after concentration, 50 ml of
each concentrated ataxin-3 sample was applied on a
Superose 12 10/300 GL column (Amersham Biosciences)
equilibrated in buffer A, at room temperature. The gel-
filtration column was calibrated with gel-filtration
standard proteins (Amersham Biosciences), with the
following elution volumes: thyroglobulin (669 kDa),
8.65 ml; aldolase (158 kDa), 11.72 ml; bovine serum
albumin (67 kDa), 12.67 ml; ovalbumin (43 kDa),
13.54 ml; chymotrypsinogen A (25 kDa), 15.20 ml; ribo-
nuclease A (13.7 kDa), 15.69 ml. The void volume of the
column was determined by applying blue dextran, which
eluted at 8.21 ml. The apparent molecular mass values
(Mapp) were calculated from an interpolation of a semi-log
plot of partition coefficient (Kav) of the protein standards
versus molecular mass.Crosslinking with glutaraldehyde
A sample (10 ml) of 0.1 mg/ml of purified protein in
buffer A was mixed with a freshly prepared 0.02% (v/v)
glutaraldehyde solution, and incubated at room tempera-
ture. The reactions were allowed to proceed for 1 min,
5 min, 10 min and 20 min, and stopped by addition of
10 ml of 2! SDS sample buffer, followed by heating to
100 8C for 5 min. Samples were analyzed by SDS-PAGE.Thioflavin-T staining
This assay is based on a previously described
protocol.59 Briefly, ThT (final concentration 30 mM) was
added to 100 mg of protein in 50 mM glycine/NaOH
buffer (pH 9.0), in an assay volume of 1 ml. Excitation and
emission slits were set at 5 nm and 10 nm, respectively.
652 Trapping Early Oligomers of Non-expanded Ataxin-3The excitation spectra (400–500 nm) were recorded by
spectrofluorimetry (FP-770; JASCO) at 25 8C with emis-
sion recorded at 482.0 nm.
Fibril formation and seeding effects monitored by the
ThT fluorescence assay
Series of solutions (1 ml) of human ataxin-3 (14Q) were
prepared (0.3 mg/ml) in buffer B (20 mM Hepes (pH 7.5),
200 mM NaCl, 5 mM EDTA, 1 mM DTT, 1 mM PMSF).
Solutions of monomers, monomers plus preformed
dimeric species (4%, w/w) and monomers plus HMM
soluble oligomers (10%, w/w), were incubated at 37 8C
along with a blank buffer solution. ThT fluorescence was
monitored over a period of 90 h in a SPECTRAmax
microplate spectrofluorimeter at 37 8C. The fluorescence
measurements were performed as follows. At increasing
incubation times, 100 ml of the protein solutions and of the
blank buffer solution were added to 150 ml of 16.7 mM ThT
in 50 mM glycine/NaOH buffer (pH 9.0) (ThT final
concentration 10 mM). The fluorescence was measured
immediately setting the excitation wavelength to 440 nm
and collecting the emission at 482 nm. The values
obtained for the protein solutions were corrected with
the blank buffer reading.
Circular dichroism
Synchrotron Radiation CD spectra were collected on
beam line CD12 of the CLRC Daresbury Laboratory’s
Synchrotron Radiation Source (SRS). Spectrosil cuvettes
of 0.05 mm, 0.02 mm and 0.01 mm pathlengths were used
with protein samples at concentrations of 2.1–12.6 mg/ml
in buffer A. The spectra were measured at 4 8C between
170 nm and 260 nm, corrected with a blank buffer reading
and scaled to molar ellipticity using the CD spectrum of
(C)-10-camphorsulfonic acid at 1 mg/ml. The analysis of
the secondary structure content was performed with
Contin, Selcon and CDsstr methods. Spectra deconvolu-
tion results were very consistent for the three methods
although, for most spectra, the lowest experimental/
calculated RMSD was achieved with the Contin method.
Congo red staining
Ataxin-3 soluble oligomers and aggregates were
incubated for 20 min with 80% (v/v) ethanol saturated
with NaCl followed by 1% (w/w) Congo red in 80%
alkaline ethanol saturated with NaCl and left to dry onto
microscopy slides. The samples were examined for
birefringence under polarized light in an Olympus
polarization light microscope.
Electron microscopy
EM images were acquired using a Zeiss (60 kV) electron
microscope. For each experiment, 10 ml of protein solution
was placed on a formvar and carbon-coated grid and
blotted off after 5 min. The sample was then stained with
3 ml of (2%, w/v) uranyl acetate, dried and observed at a
magnification of 10,000–25,000!.
Dot blot assay
Samples (1 mg) of HMM oligomers, multimers and
monomers of the recombinant proteins were applied to a
nitrocellulose membrane, blocked with non-fat milk in
Tris-buffered saline (TBS) containing 0.01% (v/v) Tween20 (TBS-T), at room temperature for 1 h, washed three
times for 5 min each with TBS-T and incubated for 1 h at
room temperature with the oligomer-specific antibody
kindly provided by C.G. Glabe (0.1 mg/ml in 3% (w/v)
BSA in TBS-T)16 or with the anti-His antibody
(Amersham Biosciences) (1:10,000 (v/v) in 3% BSA in
TBS-T). The membranes were washed three times for
5 min each with TBS-T, incubated with alkaline-phospha-
tase conjugated anti-rabbit IgG or anti-mouse IgG
(Amersham-Pharmacia) diluted 1:10,000 (v/v) in 3%
BSA in TBS-T and incubated for 1 h at room temperature.
The blots were washed three times for 5 min each with
TBS-T and developed with the ECF kit (Amersham
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